About: Comparison of Venous Thromboembolism Risks Between COVID-19 Pneumonia and Community-Acquired Pneumonia Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of Venous Thromboembolism Risks Between COVID-19 Pneumonia and Community-Acquired Pneumonia Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Comparison of Venous Thromboembolism Risks Between COVID-19 Pneumonia and Community-Acquired Pneumonia Patients
Creator	Li, Yu Biol, Vasc Thromb, Arterioscler Fan, Jiawei Guan, Wenfei Huang, Mingkui Liang, Zhenzhen Mei, Fei Sun, Jianfeng Wang, Kewei Yuan, Jinhua Zhang, Wayne
source	Medline; PMC
abstract	OBJECTIVE: The objectives were to investigate and compare the risks and incidences of venous thromboembolism (VTE) between the 2 groups of patients with coronavirus disease 2019 (COVID-19) pneumonia and community-acquired pneumonia (CAP). APPROACH AND RESULTS: Medical records of 616 pneumonia patients who were admitted to the Yichang Central People’s Hospital in Hubei, China, from January 1 to March 23, 2020, were retrospectively reviewed. The patients with COVID-19 pneumonia were treated in the dedicated COVID-19 units, and the patients with CAP were admitted to regular hospital campus. Risks of VTE were assessed using the Padua prediction score. All the patients received pharmaceutical or mechanical VTE prophylaxis. VTE was diagnosed using Duplex ultrasound or computed tomography pulmonary angiogram. Differences between COVID-19 and CAP groups were compared statistically. All statistical tests were 2 sided, and P<0.05 was considered as statistically significant. All data managements and analyses were performed by IBM SPSS, version 24, software (SPSS, Inc, Chicago, IL). Of the 616 patients, 256 had COVID-19 pneumonia and 360 patients had CAP. The overall rate of VTE was 2% in COVID-19 pneumonia group and 3.6% in CAP group, respectively (P=0.229). In these two groups, 15.6% of the COVID-19 pneumonia patients and 10% of the CAP patients were categorized as high risk for VTE (Padua score, >4), which were significantly different (P=0.036). In those high-risk patients, the incidence of VTE was 12.5% in COVID-19 pneumonia group and 16.7% in CAP group (P=0.606). Subgroup analysis of the critically ill patients showed that VTE rate was 6.7% in COVID-19 group versus 13% in CAP group (P=0.484). In-hospital mortality of COVID-19 and CAP was 6.3% and 3.9%, respectively (P=0.180). CONCLUSIONS: Our study suggested that COVID-19 pneumonia was associated with hypercoagulable state. However, the rate of VTE in COVID-19 pneumonia patients was not significantly higher than that in CAP patients.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.1161/atvbaha.120.314779
bibo:pmid	32628040
has license	no-cc
sha1sum (hex)	f7ea36acfac2583730c639165f8d69c66ec40fae
schema:url	https://doi.org/10.1161/atvbaha.120.314779
resource representing a document's title	Comparison of Venous Thromboembolism Risks Between COVID-19 Pneumonia and Community-Acquired Pneumonia Patients
has PubMed Central identifier	PMC7446987
has PubMed identifier	32628040
schema:publication	Arterioscler Thromb Vasc Biol
resource representing a document's body	covid:f7ea36acfac2583730c639165f8d69c66ec40fae#body_text
is schema:about of	named entity 'Pneumonia' named entity 'Vascular' named entity 'Venous' named entity 'high-risk' named entity 'high-risk' named entity 'VTE' named entity 'prophylaxis' named entity 'significant difference' named entity 'COVID' named entity 'VTE' named entity 'infection' named entity 'COVID' named entity 'COVID' named entity 'COVID' named entity 'comorbidities' named entity 'infection' named entity 'viruses' named entity 'mortality rate' named entity 'COVID' named entity 'cerebrovascular disease' named entity 'liver' named entity 'VTE' named entity 'pneumonia' named entity 'VTE' named entity 'RT-PCR test' named entity 'VTE' named entity 'pneumonia' named entity 'SARS-CoV-2' named entity 'thrombotic' named entity 'COVID' named entity 'CAP' named entity 'reverse transcription polymerase chain reaction' named entity 'COVID-19' named entity 'asymptomatic' named entity 'CAP' named entity 'contraindicated' named entity 'COVID' named entity 'statistically significant' named entity 'CAP' named entity 'pneumonia' named entity 'pneumonia' named entity 'statistical difference' named entity 'prophylaxis' named entity 'Cytokine storm' named entity 'false negative' named entity 'hypercoagulable state' named entity 'COVID' named entity 'Subgroup analysis' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'prophylaxis' named entity 'severe acute respiratory syndrome' named entity 'VTE' named entity 'pneumonia' named entity 'pneumonia' named entity 'VTE' named entity 'VTE' named entity 'SARS-CoV-2' named entity 'Institutional Review Board' named entity 'SPSS' named entity 'critically ill patients' named entity 'CAP' named entity 'ventilator support' named entity 'VTE' named entity 'VTE' named entity 'COVID-19' named entity 'fever' named entity 'gangrene' named entity 'hypoxia' named entity 'VTE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software